Postoperative morbidity adversely impacts oncological prognosis after curative resection for hilar cholangiocarcinoma

Table 2 Comparisons of patients’ clinicopathologic and operative variables between those with and without postoperative morbidity

Variables	Total (n = 239)	Without postoperative morbidity (n = 93)	With postoperative morbidity (n = 146)	P value
Age > 60 yr	54 (22.6)	22 (23.7)	32 (21.9)	0.754
Male sex	144 (60.3)	54 (58.1)	90 (61.6)	0.581
ASA score > 2	23 (9.6)	6 (6.5)	17 (11.6)	0.185
Obesity	28 (11.7)	4 (4.3)	24 (16.4)	0.004
Diabetes mellitus	24 (10.0)	4 (4.3)	20 (13.7)	0.018
Cirrhosis	39 (16.3)	8 (8.6)	31 (21.2)	0.010
Preoperative CA19-9 > 150 U/L	129 (54.0)	44 (47.3)	85 (58.2)	0.099
Maximum tumor size > 3 cm	68 (25.8)	21 (22.6)	47 (32.2)	0.108
Macrovascular invasion	144 (60.3)	55 (59.1)	89 (61.0)	0.779
Microvascular invasion	85 (35.6)	28 (30.1)	57 (39.0)	0.160
Peripheral nerve invasion	80 (33.5)	30 (32.3)	50 (34.2)	0.751
Poor tumor differentiation	77 (32.2)	29 (31.2)	48 (32.9)	0.785
Intraoperative blood transfusion	159 (66.5)	57 (61.3)	102 (69.9)	0.171
Intraoperative blood loss > 500 mL	185 (77.4)	65 (69.9)	120 (82.2)	0.027
Major hepatectomy	171 (71.5)	65 (69.9)	106 (72.6)	0.651
Hepatic artery reconstruction	12 (5.0)	5 (5.4)	7 (4.8)	0.841
Portal vein reconstruction	45 (19.6)	22 (23.7)	23 (15.8)	0.128
Pringle maneuver	175 (73.2)	73 (78.5)	102 (69.9)	0.142
Number of examined LNs > 4	125 (52.3)	52 (55.9)	73 (50.0)	0.372
LN metastasis	54 (22.6)	18 (19.4)	36 (24.7)	0.339
Bismuth type, III-IV	135 (56.5)	52 (55.9)	83 (56.8)	0.887
Preoperative drainage	71 (29.7)	28 (30.1)	43 (29.5)	0.914

ASA: American Society of Anesthesiologists; CA19-9: Carbohydrate antigen 19-9; LN: Lymph node.